Engineered Adipose-Derived Stem Cells Overexpressing RXFP1 via CRISPR Activation Ameliorate Erectile Dysfunction in Diabetic Rats
Antioxidants · 11.01.2023 · 12 (1) · 171
DOI: 10.3390/antiox12010171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 11.01.2023. Verfasst von Taotao Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Due to the high incidence of diabetes mellitus (DM) and poor response to the first-line treatment of DM-induced erectile dysfunction (DMED), new therapeutic strategies for DMED are needed. Adipose-derived stem cell (ADSC) transplantation is considered a promising treatment modality for DMED but is limited by poor survival and efficacy after transplantation. In this study, we aimed to increase the therapeutic effect of DMED by overexpressing the relaxin family peptide receptor 1 (RXFP1) using a clustered regularly interspaced short palindromic repeats activation (CRISPRa) system in ADSCs. Two lentiviruses carrying the CRISPRa system transfected ADSCs to overexpress RXFP1 (RXFP1-ADSCs). The intracavernous injection of ADSCs was performed in DMED rats induced by the intraperitoneal injection of streptozotocin. Four weeks after transplantation, we measured erectile function and collected specimens of the corpus cavernosum for follow-up detection. The results showed that ADSCs improved erectile function in diabetic rats, and the RXFP1-ADSCs were more significant. We detected reduced levels of oxidative stress, apoptosis and fibrosis together with relative normalization of endothelial and smooth muscle cell function in the penis after ADSC transplantation. RXFP1-ADSCs had more potent efficacy in the above alterations compared to negative control ADSCs due to the high levels of survival and paracrine capacity in RXFP1-ADSCs. The results revealed that RXFP1-ADSC transplantation could partially preserve erectile function in DMED rats associated with the regulation of oxidative stress, apoptosis, fibrosis and endothelial and smooth muscle cell dysfunction. RXFP1 may be the new target for the genetic modification of ADSCs, which benefits the management of DMED.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Taotao Sun, Wenchao Xu, Kang Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, T., Xu, W., Tu, B., Wang, T., Liu, J., Liu, K., & Luan, Y. (2023). Engineered Adipose-Derived Stem Cells Overexpressing RXFP1 via CRISPR Activation Ameliorate Erectile Dysfunction in Diabetic Rats. Antioxidants, 12(1), 171. https://doi.org/10.3390/antiox12010171
Vancouver
Sun T, Xu W, Tu B, Wang T, Liu J, Liu K, et al. Engineered Adipose-Derived Stem Cells Overexpressing RXFP1 via CRISPR Activation Ameliorate Erectile Dysfunction in Diabetic Rats. Antioxidants. 2023;12(1):171. doi:10.3390/antiox12010171
BibTeX
@article{Sun2023,
author = {Sun, Taotao and Xu, Wenchao and Tu, Bocheng and Wang, Tao and Liu, Jihong and Liu, Kang and Luan, Yang},
title = {Engineered Adipose-Derived Stem Cells Overexpressing RXFP1 via CRISPR Activation Ameliorate Erectile Dysfunction in Diabetic Rats},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {1},
pages = {171},
doi = {10.3390/antiox12010171}
}
EUVIMED